Tarsus Pharmaceuticals (TARS) Stock Analysis & AI Equity Report
Tarsus Pharmaceuticals (TARS) overview
Tarsus Pharmaceuticals (TARS) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 451m and operating profit of USD -71.0m; the year-end share price was 81.88 USD and market capitalisation was USD 3,484m. Tarsus Pharmaceuticals is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Tarsus Pharmaceuticals's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Tarsus Pharmaceuticals
Tarsus Pharmaceuticals is a commercial-stage biopharmaceutical company developing and commercializing therapeutics, initially focused on eye care. Its marketed product XDEMVY is an ophthalmic solution for Demodex blepharitis. The company also investigates lotilaner-based candidates, including a gel formulation for ocular rosacea and an oral tablet for Lyme disease prophylaxis and community malaria reduction, serving patients with these conditions.
Generate the Tarsus Pharmaceuticals report
Tarsus Pharmaceuticals is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Tarsus Pharmaceuticals and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Tarsus Pharmaceuticals
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.